Metabolic syndrome continues to be one of the major causes of mortality and morbidity in populations worldwide with an ever increasing incidence due to dietary and lifestyle changes. Statins are widely prescribed in patients of Metabolic syndrome for treatment of dyslipidemia and other pleiotropic effects. Rosuvastatin also called as superstatin, is a newer analogue with less number of studies especially in the Indian population. This book evaluates whether Rosuvastatin alone, or a combination of Atorvastatin and Ezetimibe would be a better alternative in treating dyslipidemia in patients of Metabolic syndrome. This book is beneficial to both clinicians as well as academicians. It helps the clinicians to choose a better alternative depending on the patient characteristics and helps basic medical scientists to pursue further research in this domain.